| abstract |
Therapeutic oral formulations comprising particular substituted pyridine-based compounds, their manufacture, and methods and uses of such formulations in the treatment of substance P-mediated pathways in the brain, such as elevated intracranial pressure or modification of protein expression, are described. (hyper)phosphorylated tau(t) in the brain for indications such as, but not limited to, concussion, post-concussion (or post-concussion) syndrome (PCS), chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI) and stroke. |